Safety of biologic therapy in kidney and liver transplant recipients with systemic inflammatory diseases: a real-world study from Israel
Authors' conclusion
This real-world cohort with 5-year follow-up since the post-SOT biologic initiation supported the feasibility of biologic therapy in SOT recipients with SIDs.
Study context
- Population
- Kidney and liver solid-organ transplant (SOT) recipients with systemic inflammatory diseases, Israel, 2000–2024matched cohort
- Participants
- 20 vs 56
- Exposure
- Biologic-treated SOT recipients with systemic inflammatory diseases (SIDs) vs matched SOT controls without SIDs, not treated with biologics
- Biologic-treatedn = 20
- Controlsn = 56reference
- Outcome
- Serious infections post-transplant
Methodological detailsmatched controls, Kaplan-Meier survival analysis
- Matched controls
- Kaplan-Meier survival analysis
Main finding
As reported in the abstract
Serious infections
P = 0.15
Observational data: associations, not effects.
Further findings
Events
| Outcome | Biologic-treated | Controls | P value |
|---|---|---|---|
| Deaths | 2 | 0 | P = 0.003 |
| Deaths | 2 | 0 | P = 0.003 |
- Deaths: one attributed to COVID-19 infection and one from a car accident
- Deaths: one attributed to COVID-19 infection and one from a car accident
Safety
Recurrent serious infections
P = 0.029
Cancer
P = 0.3
| Outcome | Biologic-treated | Controls |
|---|---|---|
| Graft rejection | 0 events | 5.37% |
Opportunistic infections
- No opportunistic infections were observed
Biologic treatment discontinuation
- Cases of biologic treatment discontinuation, mainly due to loss of efficacy
- 6
Original publication
Safety of biologic therapy in kidney and liver transplant recipients with systemic inflammatory diseases: a real-world study from Israel. Rheumatology (Oxford). Published 3 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →